Stephens initiated coverage on Thermo Fisher with a new price target
$TMO
Industrial Machinery/Components
Industrials
Stephens initiated coverage of Thermo Fisher with a rating of Overweight and set a new price target of $680.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $630.00 | Mkt Perform → Outperform | Bernstein |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 10/1/2024 | $680.00 | Overweight | Stephens |
| 8/28/2024 | $670.00 | Overweight | Wells Fargo |
| 6/3/2024 | $650.00 | Buy | Jefferies |
| 3/18/2024 | $620.00 | Neutral | Citigroup |
| 1/24/2024 | $475.00 → $555.00 | Overweight → Equal Weight | Barclays |
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on April 15, 2025, to shareholders of record as of March 14, 2025. This reflects an 10% increase over the previous dividend payment of $0.39. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter revenue grew 5% to $11.40 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 14% to $4.78. Fourth quarter adjusted EPS grew 8% to $6.10. Full year revenue was $42.88 billion, flat versus prior year. Full year GAAP diluted earnings per share (EPS) grew 7% to $16.53. Full year adjusted EPS grew 1% to $21.86. Further strengthened our industry leadership throughout the year by advancing our trusted partner status with cu
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 706921. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of ou
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
10-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced the launch of the Thermo Scientific Vulcan™ Automated Lab, a groundbreaking solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318064982/en/ The rapid evolution and miniaturization of semiconductor technology is leading to unprecedented demand for atomic-scale transmission el
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE:TMO) ("Thermo Fisher"). Trian issued the following statement: "Trian commends Solventum on the announced sale of its Purification & Filtration business and believes this is an important first step in the Company's value creation journey. We believe that part of what attracted strategic interest at such a high valuation multiple was the di
Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder valueStrengthens balance sheet with proceeds to be used primarily for debt paydownST. PAUL, Minn., Feb. 25, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") for $4.1 billion. Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4 billion in net proceeds, which it intends to use primarily to pay down debt. The transaction is expected to be completed by the end of 2025, s
Bernstein upgraded Thermo Fisher from Mkt Perform to Outperform and set a new price target of $630.00
Scotiabank initiated coverage of Thermo Fisher with a rating of Sector Perform
Redburn Atlantic initiated coverage of Thermo Fisher with a rating of Buy
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel